Last update 01 Nov 2024
Jiangsu Kunli Biopharmaceutical Co., Ltd.
Private Company|
2018|
Jiangsu Sheng, China
Last update 01 Nov 2024
Overview
Basic Info
Introduction Jiangsu Kunli Biopharmaceutical Co. Ltd. is a privately-owned enterprise based in China. As a biotechnology corporation, the company specializes in the production of bio-pharmaceuticals. |
Tags
Respiratory Diseases
Infectious Diseases
Nervous System Diseases
Prophylactic vaccine
Conjugated vaccine
Vaccine
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
No Data
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
评价20价肺炎球菌多糖结合疫苗在6周龄及以上健康人群中接种的安全性、耐受性和初步探索免疫原性的Ⅰ期临床试验
[Translation] A phase I clinical trial to evaluate the safety, tolerability and preliminary exploration of immunogenicity of 20-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 6 weeks and above
评价24价肺炎球菌多糖结合疫苗在18周岁及以上人群中接种的安全性和耐受性的I期临床试验和评价24价肺炎球菌多糖结合疫苗在65周岁及以上人群中接种的安全性和免疫原性的Ⅱ期临床试验
[Translation] A phase I clinical trial to evaluate the safety and tolerability of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 18 years and above, and a phase II clinical trial to evaluate the safety and immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 65 years and above
评价13价肺炎球菌多糖结合疫苗在2月龄（最小满6周龄）及以上健康人群中接种的安全性、耐受性和初步探索免疫原性的Ⅰ期临床试验
[Translation] A phase I clinical trial to evaluate the safety, tolerability and preliminary exploration of immunogenicity of 13-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) and above
100 Clinical Results associated with Jiangsu Kunli Biopharmaceutical Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Jiangsu Kunli Biopharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Jiangsu Kunli Biopharmaceutical Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 23 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
2
1
Phase 2 Clinical
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free